Cellular immune response – Page 10 – Communicable Diseases Research

Status of Humoral and Cellular Immune Responses within 12 Months following CoronaVac Vaccination against COVID-19

COVID-19에 대한 CoronaVac 백신 접종 후 12개월 이내에 체액 및 세포 면역 반응의 상태

Article

Published on 2022-06-282022-09-11
Journal: mBio [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술,

The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection

세포 면역의 견고함이 SARS-CoV-2 감염의 운명을 결정합니다

Review

Published on 2022-06-272022-09-11
Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 치료제,

[키워드] addition Administered Analysis antibody secreting cells antiviral cytokine antiviral cytokines antiviral immunity antiviral response appearance approach autosomal recessive axis B cell booster dose breadth CD4+ CD4+ T cell CD8+ Cell cellular Cellular immune response cellular immunity component contribute coordinating correlated COVID-19 COVID-19 patient Critical cross-protection Cytokines cytotoxic lymphocytes cytotoxic T lymphocytes described disease Disease progression disease severity dysregulated evasion Evolution follicular functional Germinal center global pandemic greater helper T cells humoral IFN-γ immune protection immune system Immunity in some infected cells Infection infection control inflammatory cascade innate immune system killing knowledge long-lasting lymphocyte Lymphocytes magnitude memory modulating neutralizing antibody pathogenic inflammation phenotypic pro-inflammatory cytokine pro-inflammatory cytokines protective immunity reported responsible robustness SARS-CoV-2 SARS-CoV-2 virus secreting severe COVID-19 severity Stage stages T cell T cell response T cell responses T cells T helper cell T helper cells Tfh Tfh cells the SARS-CoV-2 virus thought TNF-α vaccination Vaccine viral replication X-linked
[DOI] 10.3389/fimmu.2022.904686 PMC 바로가기 [Article Type] Review

Humoral and Cellular Immune Response After a 3-Dose Heterologous SARS-CoV-2 Vaccination Using the mRNA-BNT162b2 and Viral Vector Ad26COVS1 Vaccine in Hemodialysis Patients

혈액 투석 환자에서 mRNA-BNT162b2 및 바이러스 벡터 Ad26COVS1 백신을 사용한 3회 용량 이종 SARS-CoV-2 백신 접종 후 체액 및 세포 면역 반응

Observational Study

Published on 2022-06-232022-09-12
Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 임상, 진단,

Immune Response and Safety of SARS-CoV-2 mRNA-1273 Vaccine in Patients With Myasthenia Gravis

중증 근무력증 환자에서 SARS-CoV-2 mRNA-1273 백신의 면역 반응 및 안전성

Observational Study

Published on 2022-06-212022-09-12
Journal: Neurology® neuroimmunology & neuroinflammation [Category] COVID19(2023년), MERS, SARS, 임상, 진단,

[키워드] 95% CI activity adverse event AEs baseline blood sample cellular Cellular immune response cellular response changes in class classification clinical clinically collected Combined therapy conducted coronavirus disease correlated country Course COVID-19 determine doses Efficacy ELISA Evidence first dose humoral immune response immunosuppressive drug immunosuppressive therapy induce interferon gamma Messenger RNA mRNA mRNA vaccination mRNA-1273 mRNA-1273 vaccine Myasthenia occurred Participants Patient performed plasma Prednisone Primary outcome Prospective Study provide receiving response Safe Safety SARS-CoV-2 second dose Seroconversion significant changes in statistically significant Surveillance Symptom T-cell T-cell Response the disease the patient vaccination vaccination schedule Vaccine were assessed were measured worsening
[DOI] 10.1212/NXI.0000000000200002 PMC 바로가기 [Article Type] Observational Study

Salivary, serological, and cellular immune response to the CoronaVac vaccine in health care workers with or without previous COVID-19

이전 COVID-19 유무에 관계없이 의료 종사자의 CoronaVac 백신에 대한 타액, 혈청 및 세포 면역 반응

Article

Published on 2022-06-162022-09-11
Journal: Scientific Reports [Category] COVID19(2023년), MERS, SARS, 변종, 진단, 치료기술,

[키워드] analysed anti-SARS-CoV-2 antibodies Cellular immune response chemiluminescence CoronaVac COVID-19 Delta dose ELISA evaluated Evidence flow cytometry Gamma Health care Health care worker health care workers IFN-γ IFN-γ producing T cells IgA IgG anti-spike antibody IgG antibodies IgG antibody immunized inactivated individual individuals induce infected individuals interferon investigated neutralization test Neutralizing activity post-vaccine response producing provide reactive reduced reference strain response Saliva salivary SARS-CoV-2 SARS-CoV-2 variant serological serum serum antibodies serum antibody specific serum Spike protein T cell T cells T-cell the spike protein uninfected vaccinated individual vaccinated individuals Vaccine variable variants virus virus neutralization test
[DOI] 10.1038/s41598-022-14283-x PMC 바로가기 [Article Type] Article

Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC]

건강한 개인에서 다양한 COVID-19 백신 조합의 안전성 및 면역원성 평가: 무작위, 피험자 맹검, 대조 3상 시험을 위한 연구 프로토콜 [PRIBIVAC]

Article

Published on 2022-06-162022-09-11
Journal: Trials [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단,

[키워드] adverse event adverse events anti-SARS-CoV-2 antibodies antibody approval best blood sample Blood samples BNT162b2 boost booster booster dose booster vaccinations cellular Cellular immune response collected Combination Comprehensive control arm Controlled clinical trial CoronaVac country COVID-19 COVID-19 vaccination COVID-19 vaccine COVID-19 vaccines demonstration different time point different time points dose Effectiveness Eligible participants Endpoint enrolment evade excluded group healthy Heterologous homologous host immunity humoral immune immune profiling immune response Immunity Immunocompromised immunogenicity Immunoglobulin immunoglobulins Inactivated vaccine Infection Intervention intervention arm Laboratory test Laboratory tests Local maintain mRNA mRNA vaccine mRNA-1273 omicron over parameters participant performed persistence phase Phase 3 phase 3 trial physical population immunity pregnant primary endpoint Probability quantity raising randomization Randomized Randomized controlled trial regimen Regulatory SARS-CoV-2 SARS-COV-2 infection Serious Adverse Event Serious Adverse Events Singapore Study protocol vaccination Vaccine vaccine availability vaccine booster vaccine candidate variants variants of concern volunteers wildtype
[DOI] 10.1186/s13063-022-06345-2 PMC 바로가기 [Article Type] Article

Favorable vaccine-induced SARS-CoV-2-specific T cell response profile in patients undergoing immune-modifying therapies

면역 조절 요법을 받는 환자에서 유리한 백신 유도 SARS-CoV-2 특이적 T 세포 반응 프로파일

Article

Published on 2022-06-152022-09-12
Journal: The Journal of Clinical Investigation [Category] COVID19(2023년), MERS, SARS, 진단,

Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations

류마티스성 근골격계 질환의 면역억제제 치료는 SARS-CoV-2 감염에 대한 체액 반응의 유발을 억제하지 않고 이펙터 면역 세포 집단을 보존합니다

Article

Published on 2022-06-102022-09-11
Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 치료법,

[키워드] adaptive addition affected Analysis antibody Antibody Response Antibody responses Arthritis B lymphocytes biologic carried Cellular immune response COVID-19 CTLA4 disease disease-modifying anti-rheumatic drug Disease-modifying anti-rheumatic drugs Diseases DMARD drug effector elicit functional humoral Humoral and cellular immune responses immune immune cell populations immune response immune responses immune system immunological Immunosuppressant include individual Inflammatory Inflammatory arthritis inhibitor inhibitors life-threatening Musculoskeletal Neutralizing activity Pathologies Patient patients treated Population presenting provide RBD protein RBD proteins Re-infections response rheumatic musculoskeletal diseases. SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 nucleocapsid sustained the antibody response TNF-α Treatment virus
[DOI] 10.3389/fimmu.2022.873195 PMC 바로가기 [Article Type] Article

Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 Study

브라질에서 2회 용량 1차 프로토콜 및 BNT162b2 이종 부스터(Immunita-001)에서 비활성화된 바이러스(CoronaVac) 백신의 면역원성, 효과 및 안전성: 1년 기간의 후속 조치 4상 연구

Clinical Trial

Published on 2022-06-092022-09-11
Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, 치료기술,

[키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Anti-spike anti-Spike IgG anti-spike IgG antibodies Anti-spike IgG antibody antibody antibody levels Antibody titer Antibody titers approach association BNT162b2 booster booster dose Brazil Cellular immune response chemokines CoronaVac coronavirus COVID-19 COVID-19 pandemic Critical Cytokines Delta delta variant dose Effectiveness exposure to followed by growth factor Growth factors Heterologous heterologous booster highest IgG immune Immune profile immune response immunogenicity implication individual individuals Interaction maintenance male median mediators Neutralising Antibodies neutralising antibody no increase omicron Omicron variant pandemic Period phase 4 presenting protocol reduction remained respiratory restored robust Safe Safety SARS-CoV-2 Seropositivity severe acute respiratory syndrome Coronavirus significantly Spread timepoint titer titers vaccination Vaccine variant virus Year
[DOI] 10.3389/fimmu.2022.918896 PMC 바로가기 [Article Type] Clinical Trial

High Incidence of SARS-CoV-2 Variant of Concern Breakthrough Infections Despite Residual Humoral and Cellular Immunity Induced by BNT162b2 Vaccination in Healthcare Workers: A Long-Term Follow-Up Study in Belgium

의료 종사자의 BNT162b2 백신 접종으로 유도된 잔류 체액 및 세포 면역에도 불구하고 우려되는 돌발 감염의 SARS-CoV-2 변종 높은 발생: 벨기에의 장기 추적 연구

Clinical Trial

Published on 2022-06-092022-09-11
Journal: Viruses [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단,

[키워드] activated acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Adaptive immune response Alpha analyzed antibody B cell B cells Belgium binding BNT162b2 BNT162b2 vaccine Breakthrough infection breakthrough infections caused CD4 CD8 Cellular immune response cellular immunity circulating concern coronavirus COVID-19 delta variant delta VoCs domain Follow-up functional healthcare healthcare worker Healthcare workers humoral immune responses immunoassays in vitro incidence individual induced initiated interferon interferon-γ investigated Long-term follow-up Long-term monitoring mitigate MONITOR neutralization not correlated performed pseudovirus reduced reported residual respiratory SARS-CoV-2 SARS-CoV-2-specific T cell SARS-CoV-2-specific T cells serology severe acute respiratory syndrome Coronavirus single-center subject symptomatic T cells Trial vaccination Vaccine-induced immunity variant variants variants of concern was determined were assessed
[DOI] 10.3390/v14061257 PMC 바로가기 [Article Type] Clinical Trial